Down-regulation of transforming growth factor β receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 475-480

  Bae, Hyun Jin ^a   Eun, Jung Woo ^a   Noh, Ji Heon ^a   Kim, Jeong Kyu ^a   Jung, Kwang Hwa ^a   Xie, Hong Jian ^a   Park, Won Sang ^a   Lee, Jung Young ^a   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Hepatocellular carcinoma; Loss of heterozygosity; Mutation; Transforming growth factor receptor III

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; EXON; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; DOWN REGULATION; GENETICS; LIVER TUMOR; MIDDLE AGED; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; DOWN-REGULATION; FEMALE; HUMANS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 70349311867     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000459     Document Type: Article

References (28)

1. Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219, 2004.
2. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006.
3. de La Coste A, Romagnolo B, Billuart P, et al: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95: 8847-8851, 1998.
4. Pang A, Ng IO, Fan ST and Kwong YL: Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 146: 8-15, 2003.
5. Satoh S, Daigo Y, Furukawa Y, et al: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245-250, 2000.
6. Massague J: TGF-beta signal transduction. Annu Rev Biochem 67: 753-791, 1998.
7. Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358, 2000.
8. Wrana JL, Attisano L, Wieser R, Ventura F and Massague J: Mechanism of activation of the TGF-beta receptor. Nature 370: 341-347, 1994.
9. Nakao A, Imamura T, Souchelnytskyi S, et al: TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 16: 5353-5362, 1997.
10. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF and Weinberg RA: Expression cloning and characterization of the TGF-beta type III receptor. Cell 67: 797-805, 1991.
11. Derynck R and Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta 1333: F105-F150, 1997.
12. Copland JA, Luxon BA, Ajani L, et al: Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 22: 8053-8062, 2003.
13. Florio P, Ciarmela P, Reis FM, et al: Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. Eur J Endocrinol 152: 277-284, 2005.
14. Dong M, How T, Kirkbride KC, et al: The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117: 206-217, 2007.
15. Turley RS, Finger EC, Hempel N, How T, Fields TA and Blobe GC: The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 67: 1090-1098, 2007.
16. Finger EC, Turley RS, Dong M, How T, Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29: 528-535, 2008.
17. Nam SW, Park JY, Ramasamy A, et al: Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42: 809-818, 2005.
18. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V and Ingvarsson S: Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 79: 1468-1474, 1999.
19. Gordon KJ, Dong M, Chislock EM, Fields TA and Blobe GC: Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 29: 252-262, 2008.
20. Dixit H, Rao KL, Padmalatha VV, et al: Mutational analysis of the betaglycan gene-coding region in susceptibility for ovarian failure. Hum Reprod 21: 2041-2046, 2006.
21. Hempel N, How T, Dong M, Murphy SK, Fields TA and Blobe GC: Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 67: 5231-5238, 2007.
22. Martin J and Dufour JF: Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 14: 1720-1733, 2008.
23. Abou-Shady M, Baer HU, Friess H, et al: Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg 177: 209-215, 1999.
24. Ji GZ, Wang XH, Miao L, et al: Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. World J Gastroenterol 12: 644-648, 2006.
25. Song BC, Chung YH, Kim JA, et al: Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94: 175-180, 2002.
26. Tsai JF, Chuang LY, Jeng JE, et al: Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine (Baltimore) 76: 213-226, 1997.
27. Ito N, Kawata S, Tamura S, et al: Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 89: 45-48, 1995.
28. Kitisin K, Ganesan N, Tang Y, et al: Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 26: 7103-7110, 2007.